Meeting
2019 ASCO Annual Meeting
Pharmacodynamics of PI3K, MEK, and AKT inhibitors through isoform-specific measurements of MEK, ERK, AKT, and ribosomal protein S6 in needle biopsies.
Authors
William Herrick
Leidos Biomedical Research, Inc., Frederick, MD
William Herrick , Casey Kilpatrick , Dominic Esposito , Howard Stotler , Melinda G. Hollingshead , James H. Doroshow , Ralph E. Parchment , Apurva K. Srivastava
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3134)
DOI
10.1200/JCO.2019.37.15_suppl.3134
Abstract #
3134
Poster Bd #
126
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.
First Author: Sanne Huijberts
Poster
2020 ASCO Virtual Scientific Program
A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.
First Author: Elizabeth Iannotti Buchbinder
Poster
2016 Gastrointestinal Cancers Symposium
Adding targeted inhibition of PI3K and MAPK signaling pathways to standard chemotherapy in experimental pancreatic cancer.
First Author: Niranjan Awasthi
Poster
2012 ASCO Annual Meeting
Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC).
First Author: Giovanna Speranza